Day: September 24, 2020

Nicox Investors & Media Contact:Gavin Spencer communications@nicox.com +33 (0)4 97 24 53 00Investor Contact: Art Shannonarthur.shannon@bauschhealth.com(514) 856-3855(877) 281-6642 (toll free)                                                                                                 BAUSCH HEALTH ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN SEVEN COUNTRIESRecent Access Wins Also Make VYZULTA Available To More Americans and CanadiansSOPHIA ANTIPOLIS, France, and LAVAL, Quebec, Sept. 24, 2020 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”), Bausch + Lomb, a leading global eye health business, and Nicox (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that VYZULTA® (latanoprostene bunod ophthalmic solution),...

Nicox – Contacts Investisseurs et MediaGavin Spencer communications@nicox.com +33 (0)4 97 24 53 00Contact Investisseurs Art Shannonarthur.shannon@bauschhealth.com(514) 856-3855(877) 281-6642 (toll free)                                                                                                 BAUSCH HEALTH ANNONCE L’APPROBATION DE VYZULTA® (SOLUTION OPHTALMIQUE DE LATANOPROSTENE BUNOD), 0,024% DANS SEPT PAYS A CE JOURVYZULTA rendu accessible pour plus d’américains et de canadiens  SOPHIA ANTIPOLIS, France, et LAVAL, Québec, 24 septembre 2020 – Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” ou la “Société”), Bausch + Lomb, une société mondiale leader en santé oculaire, et Nicox S.A. (Euronext Paris : FR0013018124, COX, éligible PEA-PME), société internationale spécialisée en ophtalmologie, annoncent aujourd’hui l’approbation...

VirusIQ selects the WISeKey Digital Health Passport for COVID-19 to secure digital health screening, telemedicine and diagnostic servicesGeneva – September 24, 2020 – WISeKey International Holding (“WISeKey”, SIX: WIHN, NASDAQ: WKEY), a leading cybersecurity and IoT company, signed a Strategic Collaboration Agreement with ClinIQ Inc, a healthcare incubator platform, to secure digital health screening, telemedicine and diagnostic services.   ClinIQ Inc has worked with Oxford University Innovation to launch VirusIQ is a screening platform that specialises in early detection, prevention and management of virus diseases such as COVID-19. The screening platform provides private, secure and safe identity management, digital health screening, telemedicine and diagnostic services.The collaboration with ClinIQ reinforces WISeKey’s main objective...

Collaboration with CGN Nuclear Technology Development Co., Ltd  worth a minimum of EUR 100 millionLouvain-La-Neuve, Belgium, 24 September  2020 – IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces today that it has received the first payment of EUR 20 million from CGN Dasheng Electron Accelerator Technology Co., Ltd (“CGN Dasheng”). This follows the signature on 26 August 2020 of a strategic licensing deal with CGN Nuclear Technology Development Co., Ltd. (“CGNNT”), and its wholly-owned subsidiary CGN Dasheng, for the exclusive rights to IBA’s Proteus®PLUS* technology in China (see the press release here).The overall minimum deal value to IBA is EUR 100 million.Olivier Legrain, Chief Executive Officer at IBA, commented: “IBA identified China...

Premier paiement d’EUR 20 millions pour l’accord de licence stratégique en ChineCollaboration avec CGN Nuclear Technology Development Co., Ltdd’une valeur minimale d’EUR 100 millionsLouvain-La-Neuve, Belgium, 24 septembre 2020 – IBA (Ion Beam Applications S.A.), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce aujourd’hui avoir reçu le premier paiement d’EUR 20 millions de la part de CGN Dasheng Electron Accelerator Technology Co., Ltd (“CGN Dasheng”). Ce versement fait suite à la signature d’un accord de licence stratégique, annoncée le 26 août 2020, avec CGN Nuclear Technology Development Co., Ltd. (“CGNNT”), et sa filiale en propriété exclusive CGN Dasheng, pour les droits exclusifs sur la technologie Proteus®PLUS d’IBA en Chine (voir le communiqué de presse). La...

Press Release Nokia and Optus to provide IoT software solutions to Australian mining, utilities and transportation industries  Collaboration combines Nokia’s IMPACT IoT Platform with Optus services expertise and market reach Australia’s IoT market estimated to grow to USD 25 billion by 2024 24 September 2020 Sydney, Australia – Optus has selected Nokia’s IMPACT Internet of Things (IoT) platform to provide device management and data collection capabilities to their customers. Both companies have agreed on a joint go-to-market strategy to bring IoT solutions to Optus customers across multiple industry segments in Australia.Nokia’s industry leading IoT Device Management Platform (DMP) will enable Optus to provide its customers with simple access to Narrow Band-IoT device data, from low power devices, and remote device management at...

EMERYVILLE, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq: ZGNX) today announced the pricing of its offering of $200,000,000 aggregate principal amount of 2.75% convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The issuance and sale of the notes are scheduled to settle on September 28, 2020, subject to customary closing conditions. Zogenix also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date notes are first issued, up to an additional $30,000,000 principal amount of notes.The notes will be senior, unsecured obligations of Zogenix and will accrue interest at a rate of 2.75% per annum,...

紐約州水牛城, Sept. 24, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX) 是一家致力研究、開發及商業化用於治療癌症及相關疾病的新療法的全球生物製藥公司，今天宣佈，美國食品和藥品管理局 (FDA) 批准其 TCRT-ESO-A2 的研究性新藥 (IND) 申請，TCRT-ESO-A2 是一種以實體腫瘤為標靶的自體 T 細胞受體 (TCR)-T 細胞療法，其在 HLA-A*02:01 陽性患者中為 NY-ESO-1 陽性。TCRT-REX-A2 由 Axis Therapeutics Limited 開發，這是 Athenex 與香雪生命科學研究中心（「XLifeSc」）的合資企業，XLifeSC 是香雪製藥股份有限公司（深圳交易所：300147）的子公司。TCRT-REX-A2 類似 TAEST16001，是一種在中國由 XLifeSc 同時開發用於臨床應用的自身細胞為基礎的療法，因為兩種療法都具有相同的親和力增強 TCR。 Athenex 主席兼行政總裁暨 Axis Therapeutics 行政總裁 Johnson Lau 博士說：「FDA 批准 TCRT-ESO-A2 的 IND 申請是 Athenex 的另一個重要里程碑，讓我們進一步擴展基於 T 細胞的癌症免疫療法領域的腫瘤學產品系列。對於這次 IND 申請獲批，我們感到非常高興，這代表 Athenex 已有 10 項 IND 獲得 FDA 批准。我們亦對我們的合作夥伴 XLifeSc 使用 TAEST16001 在中國進行的初步研究中觀察到的初步陽性臨床訊號感到興奮。」香雪製藥主席兼行政總裁王永輝先生表示：「TCRT-ESO-A2 取得此項成就緊隨國家藥品監督管理局授予 TAEST16001 在中國的 IND，並代表我們在 Axis Therapeutics 的聯合開發團隊的成功合作。XLifeSc 已開始在中國對 TAEST16001...